CALGB 150905 (Alliance): Rituximab broadens the anti-lymphoma response by activating unlicensed NK cells

Natural killer (NK) cells contribute to clinical responses in patients treated with rituximab, but the rules determining NK cell responsiveness to mAb therapies are poorly defined. A deeper understanding of the mechanisms responsible for antibody-dependent cellular cytotoxicity (ADCC) could yield us...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cancer Immunol Res
Main Authors: Du, Juan, Lopez-Verges, Sandra, Pitcher, Brandelyn N., Johnson, Jeffrey, Jung, Sin-Ho, Zhou, Lili, Hsu, Katharine, Czuczman, Myron S., Cheson, Bruce, Kaplan, Lawrence, Lanier, Lewis L., Venstrom, Jeffrey M.
Format: Artigo
Sprog:Inglês
Udgivet: 2014
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4264658/
https://ncbi.nlm.nih.gov/pubmed/24958280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-13-0158
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker